Supplemental Materials

Analgesic effects of regional analgesic techniques in pediatric inguinal surgeries: a systematic review and network meta-analysis of randomized controlled trials

Tsung-Yu Hung, MD^a, Geng-Hao Bai, MD^b, Meng-Chen Tsai, MD^c, Ying-Chun Lin, MD, MS^{a,d,e}

- ^a Department of Anaesthesia, MacKay Memorial Hospital, Taipei, Taiwan.
- ^b Department of Education, National Taiwan University Hospital, Taipei, Taiwan.
- ^c Department of Education, Taipei Medical University Hospital, Taipei, Taiwan.
- ^d Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
- ^e MacKay Medical College, New Taipei City, Taiwan.

Table of Contents

| Section 1. Keywords and search strategy for Pubmed |
|--|
| Section 2. Characteristics of the included randomized controlled trials |
| Section 3. Risk of bias 2 quality assessment of the primary and secondary outcomes |
| Section 4. Confidence in Network Meta-analysis Rating of the primary and secondary outcomes |
| Section 5. Network plots of the secondary outcomes1 |
| Section 6. Network league table of the secondary outcomes1 |
| Section 7. Summary of the sensitivity analysis on the primary outcome based on studies with or without orchidopexies 1 |
| Section 8. Summary of the sensitivity analysis on the primary outcome by excluding high risk of bias studies |
| Section 9. Summary of the subgroup analysis on the primary outcome based on the volume of caudal block |
| Section 10. Netsplit for the primary and secondary outcomes2 |
| Section 11. Direct and indirect evidence proportion for the primary and secondary outcomes |

Abbreviations

ASA, American Society of Anesthesiologists Physical Status; Caudal, caudal block; CI, confidence interval; ESB, erector spinae block; II-IHB, ilioinguinal-iliohypogastric block, IM, intramuscular; IV, intravenous; LB, landmark-based; MD, mean difference; mon, month; NM, not mentioned; PO, per os; PRN, pro re nata; PVB, paravertebral block; QLB, quadratus lumborum block; RCTs, randomized controlled trials; RLB, retrolaminar block; SUPP, suppository; TAPB, transversus abdominis plane block; TFPB, transversalis fascia plane block; UG, ultrasound-guided; UK, the United Kingdom; USA, the United State of America; WI, wound infiltration; yr, year

Section 1. Keywords and search strategy for Pubmed

- ("child"[MeSH Terms] OR "child"[All Fields]) OR ("pediatric"[MeSH Terms] OR "pediatric"[All Fields]) OR ("infant"[MeSH Terms] OR "infant"[All Fields]) OR ("neonate"[MeSH Terms] OR "neonate"[All Fields])
- ("inguinal hernia"[MeSH Terms] OR "inguinal hernia"[All Fields]) OR ("groin"[MeSH Terms] OR "groin"[All fields]) OR ("hernia repair"[MeSH Terms] OR "hernia repair"[All Fields]) OR "herniotomy"[All fields]
- ("undescended testes"[MeSH Terms] OR "undescended testes"[All Fields]) OR ("orchidopexy"[MeSH Terms] OR "orchidopexy"[All Fields])
- ("hydrocele"[MeSH Terms] OR " hydrocele"[All Fields]) OR "hydrocelectomy"[All Fields]
- 5. ("genitourinary surgery"[MeSH Terms] OR " genitourinary surgery"[All Fields])
- 6. 2 OR 3 OR 4 OR 5
- 7. ("regional anesthesia"[MeSH Terms] OR "regional anesthesia"[All Fields])
- 8. ("caudal anesthesia"[MeSH Terms] OR "caudal anesthesia"[All Fields]) OR "caudal block"[All Fields]
- 9. ("nerve block"[MeSH Terms] OR "nerve block"[All Fields]) OR "plane block"[All Fields] OR "transversus abdominis"[All Fields] OR "erector spinae"[All Fields] OR ("quadratus lumborum"[MeSH Terms] OR "quadratus lumborum"[All Fields]) OR "rectus sheath"[All Fields] OR ("ilioinguinal"[MeSH Terms] OR "ilioinguinal"[All Fields]) OR ("ilioinguinal"[MeSH Terms] OR "ilioinguinal"[All Fields])
- "wound infiltration"[All Fields] OR ("instillation"[MeSH Terms] OR "instillation"[All Fields])
- 11. 7 OR 8 OR 9 OR 10
- 12. 1 AND 6 AND 11

Section 2. Characteristics of the included randomized controlled trials

| Author | Study | Patient | Patient Age | Surgery Type | Maintenance for General | | | Intervention | | | Routine non- opioid analgesia | In-Hos | pital Rescue Analgesia | Home F | Rescue analgesia |
|----------------------|------------|---------|-------------------|---|--------------------------------|---------------------------------|----------|----------------------------|--------|--|--|---|---|----------------------------|--|
| Year | Country | ASA PS | T allent Age | Surgery Type | anaesthesia | Technique | Case | Medic | ation | Dose | | Timing | Medication | Timing | Medication |
| Coşarcan | Tueltory | I-II | 1 9 | Elective unilateral inguinal | Sevoflurane + N ₂ O | Sacral epidural block (S2-3) | 30 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | | CHEOPS ≥10, APDS | Paracetamol PO | | |
| 2022 | Turkey | 1-11 | 1 – 8 yr | hernia operation | Sevonurane $+ N_2O$ | LB-II-IHB | 30 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | | ≥5 | Paracetamor PO | | |
| | | | | | | UG-TAPB | 20 | Ropivacaine | 0.25% | 0.4 ml kg ⁻¹ | | FLACC >4 | Paracetamol IV 15 mg kg ⁻¹ | | |
| riyadarshini 2022 | India | I - II | 2-12 yr | Elective open inguinal hernia repair | Isoflurane | UG-II-IHB | 20 | Ropivacaine | 0.25% | 0.2 ml kg ⁻¹ | Paracetamol IV 15 mg kg ⁻¹ | | | | |
| 2022 | | | | nerma repan | | UG-QLB | 20 | Ropivacaine | 0.25% | 0.4 ml kg ⁻¹ | ing Kg | If FLACC still >4 | Tramadol IV 1 mg kg ⁻¹ | | |
| Abdelbaser | | | | Elective unilateral inguinal | | UG-TFPB | 20 | Bupivacaine | 0.25% | 0.4 ml kg ⁻¹ | Diclofenac SUPP | FLACC≥4 | Paracetamol IV 10 mg kg ⁻¹ | | |
| 2021 | Egypt | I – II | 12 – 60 mon | herniorrhaphy | Sevoflurane | Control | 20 | | | | 1 mg kg ⁻¹ | If FLACC still ≥4 | Fentanyl IV 1 µg kg ⁻¹ | | |
| Alseoudy | D (| | 2 (| Unilateral inguinal | | UG-RLB | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | Paracetamol IV 10 | FLACC >5 | Fentanyl IV 0.5 µg kg ⁻¹ | | |
| 2021 | Egypt | I - II | 2 – 6 yr | herniotomy | Sevoflurane | UG-II-IHB | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | mg kg ⁻¹ | FLACC >2 | Ibuprofen PO 10 mg kg ⁻¹ | | |
| Benka | C | т | 2.5 | Elective inguinal | Dura u a fa 1 | UG-Caudal block | 30 | Levobupivacaine | | 2.5 mg kg ⁻¹ | | Comfort and 22 | Democratery of INV 15 may local | | |
| 2020 | Servia | 1 | 2 – 5 yr | herniorrhaphy | Propofol | Control | 30 | | | | | Comfort scale ≥ 3 | Paracetamol IV 15 mg kg ⁻¹ | | |
| Genç | | | | Unilateral inguinal hernia, | | UG-QLB | 20 | Bupivacaine | 0.20% | 0.5 ml kg ⁻¹ | Paracetamol IV 15 | Wong-Baker facial pain scale ≥3 | Tramadol IV 1 mg kg ⁻¹ | Wong-Baker | |
| 2020 | Turkey | I – II | 3 – 16 yr | undescended testis and hydrocele operations. | Sevoflurane | Systemic analgesic | 20 | Tramadol IV | | 1 mg kg ⁻¹ | mg kg ⁻¹ | if Wong-Baker facial pain scale still ≥3 | Morphine IV 0.1 mg kg ⁻¹ | facial pain scale ≥ 3 | Paracetamol PO |
| Karim | ~ // | | | | | UG-II-IHB | 50 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | Paracetamol IV 15 | FLACC >4 at PACU | Fentanyl IV 0.5 µg kg ⁻¹ | | - |
| 2020 | India | I - II | 6 mon – 7 yr | Elective hernia repair | Sevoflurane | WI | 50 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | mg kg ⁻¹ | FLACC >4 at ward | Paracetamol 10 mg kg ⁻¹ | FLACC >4 | Paracetamol 10 mg kg |
| Kodali | T., 41. | тт | (| To | S flamment | UG-TAPB | 31 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | | Paracetamol IV 7.5 mg kg ⁻¹ (< 10 kg), | | |
| 2020 | India | I - II | 6 mon – 8 yr | Inguinal hernia repair | Sevoflurane | Caudal block | 31 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | FLACC >4 | $15 \text{ mg kg}^{-1} (> 10 \text{ kg})$ | | |
| Kumar | India | I – II | 2 – 8 yr | Elective inguinal hernia | Sevoflurane + N ₂ O | UG-TAPB | 56 | Ropivacaine | 0.20% | 0.5 ml kg ⁻¹ | | CHEOPS ≥6 | Paracetamol PO 10 mg kg ⁻¹ | | |
| 2020 | maia | 1 – 11 | 2-8 yr | surgery | Sevonurane + N_2O | Caudal block | 56 | Ropivacaine | 0.20% | 1 ml kg ⁻¹ | | CHEOPS 20 | Paracetamol PO 10 mg kg | | |
| Öksüz | Turkey | I - II | 1 – 9 yr | Unilateral inguinal hernia repair and orchiopexy | Sevoflurane | UG-QLB | 27 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | Acetaminophen | FLACC >4 | Fentanyl IV 1 µg kg ⁻¹ | | |
| 2020 | Тигксу | 1-11 | 1 – 7 yr | surgery | Sevonurane | Caudal block | 25 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | IV 15 mg kg ⁻¹ | FLACC >2 | Ibuprofen PO 7 mg kg ⁻¹ | | |
| Samerchua | Thailand | I - II | 1 – 7 yr | Unilateral open inguinal | Sevoflurane + N ₂ O | UG-QLB | 19 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | _ | CHEOPS >9 at PACU | Fentanyl IV 0.5 µg kg ⁻¹ | | |
| 2020 | Thunund | 1 11 | 1 , ,1 | herniotomy | bevoltarane + 1720 | UG-II-IHB | 19 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | CHEOPS >6 at ward | Acetaminophen PO 10 mg kg ⁻¹ | | |
| Ahmad | Pakistan | NM | 2 mon – 5 yr | Surgery for inguinal hernia, hydrocele and | NM | WI | 70 | Bupivacaine | 0.25% | 0.4 ml kg ⁻¹ | _ | FLACC≥4 | Additional analgesia | | |
| 2019 | | | - 5 | undescended testis | | Systemic analgesic | 70 | Paracetamol IV | | NM | | _ | 6 | | |
| Aksu | Turkey | I - II | 1 – 7 yr | Inguinal hernia repair, orchiopexy and | Sevoflurane + N ₂ O | UG-ESB | 28 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | Acetaminophen | FLACC >4 | Tramadol IV 1 mg kg ⁻¹ | FLACC >4 | Ibuprofen PO 7 mg kg |
| 2019 | 1 and y | | 1 / 51 | hydrocelectomy. | Secondariane - 1120 | UG-QLB | 29 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | IV 15 mg kg ⁻¹ | FLACC 2-4 | Acetaminophen PO 15 mg kg ⁻¹ | FLACC 2-4 | Acetaminophen PO 15 mg kg ⁻¹ |
| ÷ 1 | | | | Elective unilateral inguinal | | UG-TAPB | 29 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | _ | | | | |
| İpek 2019 | Turkey | I - II | 6 mon – 14 yr | hernia repair, orchiopexy and hydrocelectomy. | Sevoflurane | UG-QLB | 35 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | POAS >5 | Paracetamol IV 10 mg kg ⁻¹ | NM | Ibuprofen PO 10 mg kg |
| | | | | and hydrocelectomy. | | UG-Caudal block | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | | | | |
| Ayshvarya | India | I - II | 1 – 7 yr | Unilateral inguinal | Sevoflurane + N ₂ O | UG-TAPB | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | _ | FLACC >3 | Tramadol IV 1.5 mg kg ⁻¹ | | |
| 2018 | | | | herniotomy | - | Caudal block | 30 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | | | | |
| Öksüz | Turkey | I - II | $1-7 \mathrm{yr}$ | Unilateral inguinal hernia | Sevoflurane | UG-TAPB | 25 | Bupivacaine | 0.20% | 0.5 ml kg ⁻¹ | Acetaminophen | FLACC ≥4 | Tramadol IV 1 mg kg ⁻¹ | Not specified | Ibuprofen PO 7 mg kg PRN |
| 2017 | | | | repair or orchiopexy | | UG-QLB | 25 | Bupivacaine | 0.20% | 0.5 ml kg ⁻¹ | IV 15 mg kg ⁻¹ | FLACC >2 | Ibuprofen PO 7 mg kg ⁻¹ | | PKN |
| bu Elyazed 2016 | Egypt | I - II | 3 – 10 yr | Elective unilateral open inguinal hernia repair | Isoflurane | UG-TAPB | 30 | Bupivacaine | 0.25% | 0.4 ml kg ⁻¹ | Diclofenac SUPP 25 mg | CHEOPS >6 or OPS >5 | Paracetamol IV 15 mg kg ⁻¹ | | |
| 2010 | | | | Elective outpatient | | Control | 30 | | 0.050/ | 0.5.11.1 | 25 mg | ~5 | | | |
| Ahmed 2016 | Egypt | I - II | 1 – 5 yr | unilateral open inguinal | Sevoflurane + N_2O | UG-TAPB | 20 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | - | CHIPPS >4 | Acetaminophen SUPP 20 mg kg ⁻¹ | Not specified | Paracetamol SUPP 15 mg kg ⁻¹ |
| | | | | herniotomy Unilateral herniotomy, | | Caudal block UG-TAPB | 20 35 | Bupivacaine Bupivacaine | 0.20% | 1 ml kg ⁻¹ 1 ml kg ⁻¹ | - | | | | |
| Elbahrawy 2016 | Egypt | I - II | $1-7 \ yr$ | hydrocelectomy, and | Sevoflurane + N_2O | Caudal block | 35 | 1 | 0.25% | 1 ml kg ⁻¹ | Paracetamol SUPP 15 mg kg ⁻¹ | mCHEOPS ≥ 6 | Tramadol IV 1 mg kg ⁻¹ | | |
| avrilovska- | | | | orchidopexy | | Caudal block | 28 | Bupivacaine Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | CHEOPS, FLACC >4 | Fentanyl IV 0.5 μg kg ⁻¹ | | |
| Brzanov | Macedonia | I - II | 6 mon – 7 yr | Unilateral Inguinal Hernia Repair | Sevoflurane | | | 1 | | - | - | at PACU CHEOPS, FLACC >4 | | - | |
| 2016 | | | | | | WI | 26 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | at ward | Acetaminophen PO 15 mg kg ⁻¹ | | |
| Kendigelen | Turkey | I - II | 6 – 8 vr | Unilateral inguinal hernia | Sevoflurane | UG-TAPB | 40 | Bupivacaine | 0.25% | 0.8 ml kg ⁻¹ | 4 | VAS >4 first | Tramadol IV 1 mg kg ⁻¹ | Not specified | Ibuprofen PO 15 mg kg ⁻ PRN |
| Kendigelen 2016 | Turkey | I - II | 6 – 8 yr | Unilateral inguinal hernia surgery | Sevoflurane | WI | 40 | Bupivacaine | 0.25% | 0.8 ml kg ⁻¹ 0.4 ml kg ⁻¹ | - | VAS >4 first VAS >4 consequently | Paracetamol IV 15 mg kg ⁻¹ | Not specif | fied |

| | Г Г | | | | | | 10 | | 0.50/ | 0.2 11 -1 | | | | | 3 |
|------------------|------------|------------|-------------------|--|--------------------------------|------------------------------|----------|-----------------------|-----------------------------|---|--|----------------------------------|---|------------------------------------|--|
| Ohashi 2016 | Japan | I - II | $1-6 \ yr$ | Elective inguinal hernia repair | Sevoflurane + N_2O | UG-II-IHB | 19 | Ropivacaine | 0.5% | 0.2 ml kg ⁻¹ | Acetaminophen SUPP 15 mg kg ⁻¹ | At parents' request | Acetaminophen SUPP 15 mg kg ⁻¹ | | |
| | | | | * | | Control | 20 34 | | 0.25% | 0.5 11 -1 | Sorr 15 mg kg | | E (1071 1 -] | | |
| Sethi 2016 | India | I - II | $2-6 \ yr$ | Unilateral herniotomy and orchidopexy | Sevoflurane + N_2O | UG-TAPB | - | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | - | FLACC ≥ 3 at first 2 h | Fentanyl IV 1 µg kg ⁻¹ | - | |
| 2010 | | | | отеннореку | | Caudal block Caudal block | 36 | Bupivacaine | 0.25% | 0.75 ml kg ⁻¹ | | $FLACC \ge 3$ thereafter | Paracetamol PO 20 mg kg ⁻¹ | | |
| Toker | T (1 1 | т тт | 1 7 | Elective unilateral inguinal | | | 25 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | - | CLUDDO > 4 | | | |
| 2016 | Istanbul | I - II | 1 – 7 yr | herniorrhaphy | Sevoflurane + N_2O | LB-II-IHB | 25 | Bupivacaine | 0.25% | 0.3 ml kg ⁻¹ | - | CHIPPS ≥4 | Paracetamol IV 15 mg kg ⁻¹ | | |
| | | | | | | WI | 25 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | | Morphine PCIA | | |
| Yang 2016 | China | I - II | $2-5 \ yr$ | Selective unilateral inguinal hernia repair | Sevoflurane | UG-TAPB | 50 | Levobupivacaine | 0.25% | 0.4 ml kg ⁻¹ | - | | No continuous infusion | | |
| 2010 | | | | | | Caudal block | 50 | Levobupivacaine | 0.25% | 1 ml kg ⁻¹ | | | Bolus: 20 µg, 15 min lockout. | | |
| Kanojia 2015 | India | I - II | 1 – 12 yr | Herniotomy and orchidopexy | Sevoflurane | UG-TAPB | 29 | Ropivacaine | 0.20% | 0.3 ml kg ⁻¹ | - | VAS ≥3 | Paracetamol PO 10 mg kg ⁻¹ | | |
| 2013 | | | | oreindopexy | | Caudal block | 30 | Ropivacaine | 0.20% | 1 ml kg ⁻¹ | | | | | |
| Al-Zaben 2014 | Jordan | Ι | 2 – 12 yr | Unilateral orchidopexy | Sevoflurane | LB-II-IHB | 35 | Bupivacaine | 0.50% | 0.25 ml kg ⁻¹ | - | OPS >4 | Paracetamol SUPP 30 mg kg ⁻¹ | OPS ≥3 | Acetaminophen PO 15 mg kg ⁻¹ |
| 2014 | | | | | | Systemic analgesic | 35 | Morphine IV | | 0.1 mg kg ⁻¹ | | | | Inadequate after acetaminophen | Ibuprofen PO 5 mg kg |
| Park | | | | Elective unilateral inguinal | | LB-II-IHB | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | 4 | | | | |
| 2014 | Korean | NM | 6 mon – 7 yr | hernia repair | NM | WI | 30 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | 4 | FLACC >6 | Pethidine IV 1 mg kg ⁻¹ | | |
| | | | | | | Control | 30 | | | | | | | | |
| Akinyemi | Nigeria | T | 2 – 10 yr | Herniotomy | Halothane | Caudal block | 27 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | BPRS >3 | Pentazocine IV | NM | Paracetamol PO 20 mg |
| 2013 | Tingeria | - | 2 10 91 | | | Systemic analgesic | 30 | Pentazocine IV | | 0.5 mg kg ⁻¹ | | | | | kg ⁻¹ |
| Sahin | - 1 | | • | Unilateral inguinal hernia | | UG-TAPB | 29 | Levobupivacaine | 0.25% | 0.5 ml kg ⁻¹ | Paracetamol SUPP 40 mg kg ⁻¹ | mCHEOPS >5 | Paracetamol PO 15 mg kg ⁻¹ | | |
| 2013 | Turkey | I – II | 2 – 8 yr | repair | Sevoflurane + N ₂ O | WI | 28 | Levobupivacaine | 0.25% | 0.2 ml kg ⁻¹ | Sorr to mg ng | Unresponsive to paracetamol | Morphine IV 0.05 mg kg ⁻¹ | | |
| Abdellatif | Fount | I - II | 1 6 11 | Unilateral inguinal hernia repair, hydrocelectomy, or | Sevoflurane + N ₂ O | UG-II-IHB | 23 | Bupivacaine | 0.25% | 0.1 ml kg ⁻¹ | _ | mCHEOPS >6 | Paracetamol IV 15 mg kg ⁻¹ | Simple pain scale 2-3 | Paracetamol SUPP 15 mg kg ⁻¹ |
| 2012 | Egypt | 1 – 11 | 1 – 6 yr | orchidopexy | Sevonurane + N ₂ O | Caudal block | 24 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | | mCHEOPS 4-5 | Paracetamol SUPP 15 mg kg ⁻¹ | Still in pain after paracetamol | Ibuprofen PO 10 mg k |
| Hosseini | | | | | | Caudal block | 27 | Bupivacaine | 0.25% | 0.75 ml kg ⁻¹ | | | | | |
| Jahromi | Iran | $\rm I-II$ | 3 mon – 7 yr | Elective unilateral inguinal herniorrhaphy | Isoflurane + N ₂ O | WI | 30 | Bupivacaine | 0.50% | 0.4 ml kg ⁻¹ | | FLACC ≥4 | Meperidine IV 0.5 mg kg ⁻¹ | | |
| 2012 | | | | nermorrnapny | | Systemic analgesic | 30 | Acetaminophen SUPP | | 20 mg kg ⁻¹ | | | | | |
| Al-Zaben | | | | Unilateral Inguinal | | LB-II-IHB | 30 | Bupivacaine | 0.50% | 0.25 ml kg ⁻¹ | | | | | Paracetamol PO |
| 2011 | Jordan | Ι | 2 – 12 yr | Herniotomy | Sevoflurane + N_2O | Systemic analgesic | 30 | Morphine IV | | 0.1 mg kg ⁻¹ | | OPS >4 | Paracetamol SUPP 30 mg kg ⁻¹ | Not specified | 15 mg kg ⁻¹ |
| D : | | | | | | WI | 60 | Levobupivacaine | 0.25%(<16kg) | 1.25 mg kg ⁻¹ | | D 1 1: (1>2 | | | |
| Bari 2011 | Bangladesh | NM | $2-18 \ yr$ | Unilateral or Bilateral Inguinal Hernia Repair | NM | | (0) | Paracetamol | 0.5%(>16kg) | | - | Poker chip tool ≥2, or VAS ≥4 | Paracetamol PO 15 mg kg ⁻¹ | | |
| | | | | | | Systemic analgesic | 60 | SUPP | | 30 mg kg ⁻¹ | | | | | |
| Tug 2011 | Turkey | I - II | 3 – 7 yr | Unilateral inguinal hernia repair surgery. | Sevoflurane + N ₂ O | LB-PVB (L2) | 35 | Levobupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | FLACC >2 | Tramadol IV | | |
| 2011 | - | | - | repair surgery. | | Caudal block | 35 | Levobupivacaine | 0.25% | 1 ml kg ⁻¹ | | | | | |
| Cnar 2009 | Turkey | Ι | 2 – 10 yr | Unilateral inguinal hernia | Sevoflurane | WI | 64 | Levobupivacaine | 0.50% | 0.25 ml kg ⁻¹ | 4 | Hanallah's OPS ≥4 | Paracetamol PO 20 mg kg ⁻¹ | | |
| 2009 | - | | - | repair | | Control | 32 | | | | | | | | |
| Khalil | USA | I - II | 1 – 6 yr | Elective orchidopexy | Isoflurane + N ₂ O | Caudal block | 18 | Ropivacaine | 0.2% | 1.25 ml kg ⁻¹ | 4 | Hanallah's modified | Morphine IV 0.1 mg kg ⁻¹ | | |
| 2009 | 007 | 1 - 11 | 1 – 0 yi | Elective oreindopexy | isonurane + m20 | Systemic analgesic | 18 | Fentanyl IV | | 2 μg kg ⁻¹ , then 1 μg kg ⁻¹ | | pain score ≥4 | worphine iv 0.1 llig kg | | |
| Weintraud | South | T TY | 0.04 | Y | TT 1 -1 | UG-II-IHB | 35 | Ropivacaine | 0.50% | 0.25 ml kg ⁻¹ | | | | | |
| 2009 | Africa | I - II | 8 – 84 mon | Inguinal hernia repair | Halothane | LB-II-IHB | 31 | Ropivacaine | 0.50% | 0.25 ml kg ⁻¹ | 1 | | | | |
| Atta | _ | • •- | | Elective surgery for | a a | UG-II-IHB | 30 | Bupivacaine | 0.25% | 0.25 ml kg ⁻¹ | | | n | | |
| 2008 | Egypt | I - II | 2 – 6 yr | inguinal hernia repair | Sevoflurane + N_2O | Caudal block | 30 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | 1 | OPS ≥4 | Paracetamol PO 20 mg kg ⁻¹ | | |
| Matsota | Grand | T TT | 2 12 | Unilateral inguinal | Source + N.C. | WI | 15 | Levobupivacaine | 0.25%(<16kg) 0.5%(>16kg) | 1.25 mg kg ⁻¹ | | Poker chip tool ≥2, or | Demoster al DO 15 1 | | |
| 2007 | Greece | I – II | 2 – 12 yr | hernioplasty | Sevoflurane + N_2O | Systemic analgesic | 15 | Paracetamol SUPP | | 30 mg kg ⁻¹ | | VAS ≥4 | Paracetamol PO 15 mg kg ⁻¹ | | |
| | | | | | | Caudal block | 29 | Ropivacaine | 0.2% | 1 ml kg ⁻¹ | | | | | |
| Caetano | Duori1 | T TT | 1 5 | Elective unilateral inguinal | Halothane | | | - | | - | 1 | OPS ≥4 | Dipyrone PO 25 mg kg ⁻¹ | | |
| 2006 | Brazil | I – II | 1 – 5 yr | herniorrhaphy | Taiomane | LB-II-IHB | 29 | Ropivacaine | 0.2% | 0.6 ml kg ⁻¹ | 4 | If still OPS ≥4 | Codeine PO 1 mg kg ⁻¹ | | |
| | | | | | | WI | 29 | Ropivacaine | 0.2% | 0.5 ml kg ⁻¹ | | | | | |
| Khosravi | Iran | I - II | $2-7 \mathrm{yr}$ | Elective day-case surgical repair of unilateral inguinal | Halothane $+ N_2O$ | LB-II-IHB | 30 | Bupivacaine | 0.50% | 0.25 ml kg ⁻¹ | 4 | | | Not specified | Acetaminophen PO |
| 2006 | | | 5 | hernia. | 2 | Systemic analgesic | 30 | Tramadol IV | | 1.5 mg kg ⁻¹ | | | | L | 15 mg kg ⁻¹ |

| | | | | | | | | | | | | | | | 4 |
|-------------------|------------|--------------------------|----------------------|---|--------------------------------|--------------------|----------|----------------------------|--------|---|----------------------------|-----------------------------------|---|---------|------------------|
| Aouad | | | | | | Caudal block | 22 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | Agitated | Propacetamol IV 30 mg kg ⁻¹ | | |
| 2005 | Lebanon | NM | 2 – 6 yr | Inguinal hernia repair | Sevoflurane + N_2O | Systemic analgesic | 22 | Fentanyl IV | | 1 μg kg ⁻¹ | | Still agitated after propacetamol | Morphine IV 0.1 mg kg ⁻¹ | | |
| Samarkandi | Saudi | - | | Elective unilateral inguinal | a a | Caudal block | 30 | Bupivacaine | 0.25% | 0.75 ml kg ⁻¹ | | • • | Pethidine IM 1 mg kg ⁻¹ , or | | |
| 2005 | Arabia | I | 1 – 10 yr | herniotomy | Sevoflurane + N_2O | Systemic analgesic | 32 | Diclofenac SUPP | | 1 mg kg ⁻¹ | | Pain score reached 3 | Paracetamol SUPP 10–15 mg kg ⁻¹ | | |
| Willschke | Austria | NM | 1 mon – 8 yr | Inguinal hernia repair, orchidopexy or hydrocele | Halothane | UG-II-IHB | 50 | Levobupivacaine | 0.25% | Until both nerves were surrounded | | OPS ≥11 | Acetaminophen PO 40 mg kg ⁻¹ | | |
| 2005 | | | | repair | | LB-II-IHB | 50 | Levobupivacaine | 0.25% | 0.3 ml kg ⁻¹ | | — | 1 | | |
| Sakellaris | | | | Unilateral inguinal hernia | | WI | 30 | Ropivacaine | 0.50% | 0.25 ml kg ⁻¹ | | | | | |
| 2004 | Greece | I | 6 – 10 yr | repair | Sevoflurane | Control | 15 | | | | | Hanallah's OPS | Paracetamol SUPP PRN | | |
| Samarkandi | Saudi | т | 1 11 | Elective unilateral inguinal | Sevoflurane + N ₂ O | Caudal block | 30 | Bupivacaine | 0.25% | 0.75 ml kg ⁻¹ | | Dein and march 12 | Pethidine IM 1 mg kg ⁻¹ | | |
| 2004 | Arabia | 1 | 1 – 11 yr | herniotomy | Sevonurane + N_2O | LB-II-IHB | 30 | Bupivacaine | 0.25% | 0.25 ml kg ⁻¹ | | Pain score reached 3 | Paracetamol SUPP 125–500 mg | | |
| | | | | | | Caudal block | 15 | Ropivacaine | 0.2% | 1 ml kg ⁻¹ | | | | | |
| Shi 2004 | Korea | I - II | $2-8 \ yr$ | Unilateral and bilateral inguinal hernia sutures | Sevoflurane + N_2O | Systemic analgesic | 15 | Ketorolac IV | | 1 mg kg ⁻¹ | | | | | |
| | | | | | | Control | 15 | | | | | | | | |
| Bhattacharya | India | тп | 1 5 200 | Herniotomy and | Halothane + N ₂ O | Caudal block | 50 | Bupivacaine | 0.25% | 0.4 ml kg ⁻¹ | | OPS ≥4 | Paracetamol PO 15 mg kg ⁻¹ | | |
| 2003 | maia | I – II | 1 – 5 yr | orchidopexy operation | The formation $r_2 O$ | Systemic analgesic | 50 | Diclofenac SUPP | | 1 mg kg ⁻¹ | | | r aracetamor PO 15 mg kg - | | |
| Machotta | Germany | I – II | 0 – 5 yr | Unilateral inguinal hernia | Sevoflurane + N ₂ O | Caudal block | 30 | Bupivacaine | 0.50% | 1 ml kg ⁻¹ | | Hanallah's OPS ≥5 at PACU | Piritramide IV 0.05 mg kg ⁻¹ | | |
| 2003 | Germany | 1 – 11 | 0 – 5 yr | repair | Sevenuralie $\pm N_2O$ | WI | 28 | Bupivacaine | 0.50% | 0.2 ml kg ⁻¹ | | Not specified at ward | Acetaminophen SUPP PRN | | |
| Chae | <i>V</i> | T TT | 2 7 | In minute section 1 - 1 | Eaflure - N.O. | WI | 20 | Bupivacaine | 0.25% | 0.3 ml kg ⁻¹ | | | | | |
| 2000 | Korea | I – II | 3 – 7 yr | Inguinal herniorrhaphy | Enflurane + N_2O | Systemic analgesic | 20 | Ketorolac IV | | 1 mg kg ⁻¹ | | | | | |
| Gaitini | Israel | T | 1 Q x7m | Elective ilioinguinal | Halothane + N ₂ O | Caudal block | 20 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | mCHEOPS 4-5 | Fentanyl IV 1 µg kg ⁻¹ | | |
| 1999 | Israel | 1 | 1 – 8 yr | herniorrhaphy | The formation $+ N_2 O$ | Systemic analgesic | 20 | Fentanyl IV | | up to 2 µg kg ⁻¹ | | meneors 4-3 | rentatiyi i v i µg kg i | | |
| Klimscha | Austria | NM | 0.5 – 6 yr | Unilateral ambulatory | Halothane + N ₂ O | Caudal block | 12 | Bupivacaine | 0.25% | 0.75 ml kg ⁻¹ | | OPS >11 | Paracetamol SUPP 15 mg kg ⁻¹ | OPS >11 | Paracetamol SUPP |
| 1998 | Ausula | TATAT | 0.5 – 0 yi | hernia repair | | Control | 10 | Saline | | 0.75 ml kg ⁻¹ | | 015-11 | | 013-11 | |
| Anatol | Spain | NM | 5 – 12 yr | Groin surgery (Inguinal hernia, hydrocele, | Halothane + N ₂ O | WI | 61 | Bupivacaine | 0.50% | 0.4 ml kg ⁻¹ | | Not specified | Paracetamol 10 mg kg ⁻¹ PRN | | |
| 1997 | Spani | TATAT | 5 – 12 yi | undescended testes) | | LB-II-IHB | 55 | Bupivacaine | 0.50% | 0.4 ml kg ⁻¹ | | The specified | | | |
| Öztekin | Turkey | I - II | 6 – 8 yr | Elective unilateral inguinal | Halothane + N ₂ O | LB-II-IHB | 20 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | Hanallah's OPS >5 | Additional analgesic | | |
| 1997 | Turkey | 1 11 | 0 0 91 | hernia repair | | Control | 20 | | | | | | | | |
| Moon | Korea | I - II | 3 – 10 yr | Orchiopexy and herniorrhaphy | Enflurane + N ₂ O | Caudal block | 20 | Bupivacaine | 0.125% | 0.5 ml kg ⁻¹ | | | | | |
| 1996 | | | | herniorrhaphy | | LB-II-IHB | 20 | Bupivacaine | 0.25% | 0.3 ml kg ⁻¹ | | | | | |
| Okur | Turkey | NM | 1 mon – 2 yr | Unilateral inguinal hernia | Halothane $+ N_2O$ | WI | 20 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | Hanallah's OPS | Paracetamol SUPP PRN | | |
| 1996 | | | - | repair | | Control | 10 | | | | | | | | |
| Shenfeld 1995 | Israel | NM | 5 mon – 11 yr | Elective inguinoscrotal surgery for undescended | Halothane + N ₂ O | WI | 45 | Bupivacaine | 0.25% | 0.25 ml kg ⁻¹ | | Not specified | Meperidine IM 1 mg kg ⁻¹ PRN | | |
| 1993 | | | · · · · | testis or inguinal hernia | _ | Control | 45 | | | | | - | | | |
| Ryhänen | | ÷ | | Elective herniotomy or | Y (1 | Caudal block | 57 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | | Pethidine IV 0.5 mg kg ⁻¹ or IM 1.0 mg | | |
| 1994 | Finland | I | 11 mon – 7 yr | orchidopexy | Isoflurane + N_2O | Systemic analgesic | 70 | Diclofenac IM | | 1 mg kg ⁻¹ | | Not specified | kg ⁻¹ PRN | | |
| | | | | | | Control | 73 | | 0.250/ | 0.4 11 1 | | | | | |
| Chen | T : | , | 1 10 | Elective unilateral inguinal | T CL CY C | LB-II-IHB | 25 | Bupivacaine | 0.25% | 0.4 ml kg ⁻¹ | | | | | |
| 1991 | Taiwan | I - II | 1 – 10 yr | herniorrhaphy | Isoflurane + N ₂ O | Systemic analgesic | 25 | Fentanyl IV | | 1 μg kg ⁻¹ | | | | | |
| | | | | | Halothane or | Control | 25 | Paul 1 | 0.250/ | 07 11 -1 | | | | | |
| Schindler 1991 | Australia | I - II | 2 mon – 12 yr | Unilateral inguinal herniotomy | Isoflurane | Caudal block WI | 27 27 | Bupivacaine Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | | Not specified | Paracetamol PO or Pethidine IM PRN | | |
| | | | | | $+ N_2O$ | LB-II-IHB | 30 | Bupivacaine | 0.25% | 0.7 ml kg ⁻¹ | | | | | |
| Casey 1990 | USA | $\mathrm{I}-\mathrm{II}$ | $2-10 \mathrm{\ yr}$ | Inguinal hernia repair | Halothane + N_2O | WI | 30 | Bupivacaine | 0.25% | 0.25 ml kg ⁻¹ | | OPS ≥6 | Fentanyl IV 1–2 µg kg ⁻¹ | | |
| | | | | D · · · · | | Caudal block | 18 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | D | | | | |
| Moores 1990 | UK | NM | $1-10 \ yr$ | Day case inguinal herniotomy | Halothane + N_2O | Systemic analgesic | 20 | Diclofenac SUPP | 0.2370 | 1 mg kg ⁻¹ | Paracetamol 120– 500 mg | | | | |
| | | | | | | Caudal block | 20 | Bupivacaine | 0.25% | 1 ml kg ⁻¹ | | | A 11 150 450 D | | |
| Fell 1988 | UK | NM | NM | Unilateral inguinal herniotomy as day cases | Halothane + N_2O | WI | 27 | Bupivacaine | 0.25% | 0.5 ml kg ⁻¹ | | Not specified | Aspirin 150–450 mg or Paracetamol 120–500 mg PRN | | |
| | | | | Elective repair of a | | Caudal block | 16 | Bupivacaine | 0.25% | 2.5 ml per yr of | | | - | | |
| Hannallah 1987 | USA | $\mathrm{I}-\mathrm{II}$ | 18 mon – 12 yr | unilateral undescended | Halothane + N_2O | | | | | age | | Hanallah's OPS ${\geq}7$ | Fentanyl 1–2 µg kg ⁻¹ | | |
| | | | | testicle | | LB-II-IHB | 13 | Bupivacaine | 0.25% | 4-6 ml | | | | | |

| | | | | | | Control | 15 | | | | | | |
|---------|--------|--------|------------|--|------------------------------|--------------|----|-------------|-------|------------------------------|-----------------|---|--|
| Reid | UK | | 1 7 | Day-case inguinal | Helethene N.O. | LB-II-IHB | 27 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | | |
| 1987 | UK | NM | $1-7 \ yr$ | herniotomy | Halothane + N ₂ O | WI | 22 | Bupivacaine | 0.25% | 0.2 ml kg ⁻¹ | | | |
| Markham | UK | т | 1 – 12 yr | Herniotomy, orchidopexy or ligation of patent | Halothane + N ₂ O | Caudal block | 26 | Bupivacaine | 0.50% | 1 ml per yr of age + 2 ml | Not specified | Diamorphine 0.1 mg kg ⁻¹ PRN | |
| 1986 | UK | 1 | 1 – 12 yı | processus vaginalis | Thatothane + N_2O | LB-II-IHB | 26 | Bupivacaine | 0.50% | 0.5 ml per yr of age | Not specified | Diamorphine 0.1 mg kg PKN | |
| Tsai | | | | | | Caudal block | 50 | Bupivacaine | 0.25% | 0.1 ml per yr per seg | | | |
| 1986 | Taiwan | I - II | $2-7 \ yr$ | Inguinal herniorrhaphy | Halothane $+ N_2O$ | LB-II-IHB | 50 | Bupivacaine | 0.25% | 1-2 ml kg ⁻¹ | | | |
| | | | | | | Control | 50 | | | | | | |
| Smith | UK | NM | 1 – 10 yr | Inguinal herniotomy | Halothane + N ₂ O | LB-II-IHB | 58 | Bupivacaine | 0.50% | 0.5 ml per yr of age | Not specified | Paracetamol PRN | |
| 1982 | 011 | 1.1.1 | 1 10 91 | ingunial normotomy | 1101010000 11020 | Control | 49 | | | | i tor specifica | | |

APDS, All India Institute of Medical Science Pain Discomfort Scale; BPRS, Behavioral Pain Rating Scale; CHEOPS, Children's Hospital of Eastern Ontario Pain Scale; CHIPPS, Children's and Infants' Postoperative Pain Scale; FLACC, Face, Legs, Activity, Cry, Consolability; mCHEOPS, modified Children's Hospital of Eastern Ontario Pain Scale; POAS, Pediatric Objective Pain Scale

a. Control: comparison group that received only the standard care of the corresponding intervention group.b. Systemic analgesia: comparison group that received additional systemic analgesic to the standard care of the corresponding intervention group.

| | | | Bias due to | | | |
|--|--|--|--|--|---|--|
| Author/Year | Randomization | Deviations from intended | Missing outcome data | Measurement of the outcome | Selection of the reported results | Overall bias |
| | process | interventions | Gata | | reported results | |
| ime to the first rescue analg | esic after surgery | | | | | |
| Priyadarshini 2022 | Low | Low | Low | Low | Low | Low |
| Genc 2020 | Some concerns ^a | Low | Low | Low | Low | Some concern |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Kumar 2020 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Samerchua 2020 | Low | Low | Low | Low | Low | Low |
| İpek 2019 | Some concerns ^a | Low | Low | Low | Low | Some concern |
| Ayshvarya 2018 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Elbahrawy 2016 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concern |
| Gavrilovska-Brzanov 2016 | Some concerns ^a | Low | Low | Low | Low | Some concern |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Kanojia 2015 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Al-Zaben 2014 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Akinyemi 2013 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Sahin 2013 | Low | Low | Low | Low | Low | Low |
| Abdellatif 2012 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Hosseini Jahromi 2012 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concern |
| Al-Zaben 2011 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Bari 2011 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Cnar 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Atta 2008 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Matsota 2007 | Low | Low | Low | Low | Some concerns ^c | Some concern |
| Caetano 2006 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Samarkandi 2005 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Samarkandi 2004 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Klimscha 1998 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Shenfeld 1995 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Ryhanen 1994 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Number of patients requiring | | | | | | |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Öksüz 2020 | Some concerns ^a | Low | Low | Low | Low | Some concern |
| Samerchua 2020 | Low | Low | Low | Low | Low | Low |
| Ahmad 2019 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| | | 2011 | 2011 | 2011 | | |
| Inek 2019 | Some concerns ^a | Low | Low | Low | Low | Some concerr |
| Ípek 2019 Avshvarva 2018 | Some concerns ^a | Low | Low | Low | Low Some concerns ^c | |
| Ayshvarya 2018 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concern |
| Ayshvarya 2018 Öksüz 2017 | Some concerns ^a Low | Low Low | Low Low | Low Low | Some concerns ^c Some concerns ^c | Some concern Some concern Some concern |
| Ayshvarya 2018 Öksüz 2017 Elbahrawy 2016 | Some concerns ^a Low Some concerns ^a | Low Low Low | Low Low Low | Low Low Some concerns ^b | Some concerns ^c Some concerns ^c Low | Some concern Some concern Some concern |
| Ayshvarya 2018 Öksüz 2017 Elbahrawy 2016 Gavrilovska-Brzanov 2016 | Some concerns ^a Low Some concerns ^a Some concerns ^a | Low Low Low Low | Low Low Low Low | Low Low Some concerns ^b Low | Some concerns ^c Some concerns ^c Low Low | Some concern Some concern Some concern Some concern |
| Ayshvarya 2018 Öksüz 2017 Elbahrawy 2016 Gavrilovska-Brzanov 2016 Kendigelen 2016 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low | Low Low Low Low Low | Low Low Low Low Low | Low Low Some concerns ^b Low Low | Some concerns ^c Some concerns ^c Low Low | Some concern Some concern Some concern Some concern Low |
| Ayshvarya 2018 Öksüz 2017 Elbahrawy 2016 Gavrilovska-Brzanov 2016 Kendigelen 2016 Sethi 2016 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Low | Low Low Low Low Low Low | Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low | Some concerns ^c Some concerns ^c Low Low Low | Some concerr Some concerr Some concerr Some concerr Low Low |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Low Some concerns ^a | Low Low Low Low Low Low Low | Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Low Some concerns ^a Low | Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a | Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern High |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low | Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c | Some concerr Some concerr Some concerr Low Low Some concerr Some concerr High Low |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern High Low Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern High Low Some concern Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Some concerns ^b | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c | Some concerr Some concerr Some concerr Some concerr Low Low Some concerr Some concerr High Low Some concerr Some concerr Some concerr |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009Cnar 2009 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Some concerns ^b Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern High Low Some concern Some concern Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009Cnar 2009Caetano 2006 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Low Some concerns ^b Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c | Some concerr Some concerr Some concerr Some concerr Low Low Some concerr Some concerr Some concerr Some concerr Some concerr Some concerr Some concerr Some concerr |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009Cnar 2009Caetano 2006Aouad 2005 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Low Some concerns ^b Low Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Some concern Low Low Some concern Some concern Some concern Some concern Some concern Some concern Some concern Some concern |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009Cnar 2009Caetano 2006Aouad 2005Samarkandi 2005 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Some concerns ^b Low Low Low Low Low | Some concerns ^c Low Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c | Some concerr Some concerr Some concerr Some concerr Low Some concerr Some concerr High Low Some concerr Some concerr Some concerr Some concerr Some concerr Some concerr |
| Ayshvarya 2018Öksüz 2017Elbahrawy 2016Gavrilovska-Brzanov 2016Kendigelen 2016Sethi 2016Toker 2016Yang 2016Park 2014Sahin 2013Abdellatif 2012Hosseini Jahromi 2012Khalil 2009Cnar 2009Caetano 2006Aouad 2005 | Some concerns ^a Low Some concerns ^a Some concerns ^a Low Some concerns ^a Low Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a Some concerns ^a | Low Low Low Low Low Low Low Low Low Low | Low Low Low Low Low Low Low Low Low Low | Low Low Some concerns ^b Low Low Low Low Some concerns ^b Low Low Some concerns ^b Low Low Low | Some concerns ^c Some concerns ^c Low Low Low Some concerns ^c Some concerns ^c Some concerns ^c Low Some concerns ^c Some concerns ^c Some concerns ^c Some concerns ^c | Some concern Some concern Some concern Low Low Some concern Some concern High |

Section 3. Risk of bias 2 quality assessment of the primary and secondary outcomes

| Gaitini 1999 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
|--------------------------------|----------------------------|-----|-----|----------------------------|----------------------------|---------------|
| Anatol 1997 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Shenfeld 1995 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Ryhanen 1994 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Schindler 1991 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Moores 1990 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Casey 1990 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Reid 1987 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Number of patients requiring | | | | Low | Some concerns | Some concerns |
| Priyadarshini 2022 | Low | Low | Low | Low | Low | Low |
| Genc 2020 | Some concerns ^a | Low | Low | Low | Low | Some concerns |
| Samerchua 2020 | | Low | Low | Low | Low | |
| | Low | | | | | Low |
| Ayshvarya 2018 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Elbahrawy 2016 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concerns |
| Gavrilovska-Brzanov 2016 | Some concerns ^a | Low | Low | Low | Low | Some concerns |
| Kendigelen 2016 | Low | Low | Low | Low | Low | Low |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Yang 2016 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Park 2014 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Sahin 2013 | Low | Low | Low | Low | Low | Low |
| Hosseini Jahromi 2012 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concerns |
| Khalil 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Aouad 2005 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Machotta 2003 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Gaitini 1999 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Shenfeld 1995 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Schindler 1991 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Casey 1990 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Markham 1986 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Postoperative pain score at 0- | -2h | | | | | |
| Benka 2020 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Ahmad 2019 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Öksüz 2017 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Gavrilovska-Brzanov 2016 | Some concerns ^a | Low | Low | Low | Low | Some concerns |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Toker 2016 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Al-Zaben 2014 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Park 2014 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Al-Zaben 2011 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Cnar 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Khosravi 2006 | Low | Low | Low | Low | Low | Low |
| Sakellaris 2004 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| | | | | | | |
| Shi 2004 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Chae 2000 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Gaitini 1999 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Moon 1996 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Okur 1996 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Chen 1991 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Reid 1987 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Postoperative pain score at 4- | | | l | 1 | | |
| Benka 2020 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Ahmad 2019 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Öksüz 2017 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Toker 2016 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| | | | | | | |
| Kanojia 2015 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |

| Park 2014 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
|--------------------------------|----------------------------|-----|-----|----------------------------|----------------------------|---------------|
| Al-Zaben 2011 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Cnar 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Chae 2000 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Moon 1996 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Postoperative pain score at 8- | -12h | | | | | |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Öksüz 2017 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Toker 2016 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Shenfeld 1995 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Postoperative pain score at 24 | łh | | | | | |
| Kodali 2020 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Öksüz 2017 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Park 2014 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Cnar 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Postoperative nausea and vor | | | | Low | Some concerns | |
| Benka 2020 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Kumar 2020 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Öksüz 2020 | Some concerns ^a | Low | Low | | | |
| | | | | Low | Low | Some concerns |
| Ayshvarya 2018 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Öksüz 2017 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Abu Elyazed 2016 | Low | Low | Low | Low | Low | Low |
| Elbahrawy 2016 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concerns |
| Gavrilovska-Brzanov 2016 | Some concerns ^a | Low | Low | Low | Low | Some concerns |
| Kendigelen 2016 | Low | Low | Low | Low | Low | Low |
| Ohashi 2016 | Low | Low | Low | Low | Low | Low |
| Sethi 2016 | Low | Low | Low | Low | Low | Low |
| Yang 2016 | Low | Low | Low | Low | Some concerns ^c | Some concerns |
| Al-Zaben 2014 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Akinyemi 2013 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Sahin 2013 | Low | Low | Low | Low | Low | Low |
| Abdellatif 2012 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Hosseini Jahromi 2012 | Some concerns ^a | Low | Low | Some concerns ^b | Low | Some concerns |
| Al-Zaben 2011 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Cnar 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Khalil 2009 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Caetano 2006 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Khosravi 2006 | Low | Low | Low | Low | Low | Low |
| Bhattacharya 2003 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Anatol 1997 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Shenfeld 1995 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Chen 1991 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |
| Schindler 1991 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Moores 1990 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| | | | | | | |
| Fell 1988 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Reid 1987 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Markham 1986 | Some concerns ^a | Low | Low | Low | Some concerns ^c | Some concerns |
| Tsai 1986 | Some concerns ^a | Low | Low | Some concerns ^b | Some concerns ^c | High |

c. No information about the pre-determined trial protocol.


Section 4. Confidence in Network Meta-Analysis Rating of the primary and secondary outcomes.

| | 1 | | 8 | and secondary | | | 1 | |
|-------------------------------|---------------|-------------------|----------------|---------------|----------------|----------------|----------------|------------|
| Comparison | Number | Within-study | Reporting bias | Indirectness | Imprecision | Heterogeneity | Incoherence | Confidence |
| | of studies | bias | | | | | | rating |
| Time to the first rescue anal | gesic after : | surgery | | | | | | |
| Caudal: Control | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: LB II-IHB | 1 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Caudal: QLB | 1 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Caudal: Systemic analgesia | 4 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Caudal: TAPB | 7 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| Caudal: UG II-IHB | 2 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Caudal: WI | 3 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Control: Systemic analgesia | 1 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| Control: WI | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| LB II-IHB: Systemic analgesia | 2 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| QLB: Systemic analgesia | 1 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| QLB: TAPB | 2 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Some concerns | Very low |
| | - | | | | | | | Moderate |
| QLB: UG II-IHB | 2 | No concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | |
| Systemic analgesia: WI | 3 | Some concerns | Low risk | No concerns | No concerns | Major concerns | Major concerns | Very low |
| TAPB: UG II-IHB | | No concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| TAPB: WI | 1 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Some concerns | Very low |
| Control: LB II-IHB | 0 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| Control: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| Control: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| Control: UG II-IHB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| LB II-IHB: UG II-IHB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| LB II-IHB: WI | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| QLB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Systemic analgesia: UG II-IHB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| UG II-IHB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Number of patients requirin | g rescue an | algesics after su | rgery | | | | | |
| Caudal: Systemic analgesia | 8 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| Caudal: Control | 1 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: LB II-IHB | 3 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Caudal: QLB | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: TAPB | 6 | Some concerns | Low risk | No concerns | No concerns | Major concerns | Some concerns | Very low |
| Caudal: WI | 5 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Systemic analgesia: Control | 1 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Systemic analgesia: WI | 2 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Some concerns | Very low |
| Control: LB II-IHB | 1 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| Control: WI | 3 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| LB II-IHB: UG II-IHB | 1 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
| LB II-IHB: WI | 6 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| | 1 | | Low risk | | _ | | | • |
| UG II-IHB: QLB | 2 | No concerns | | Some concerns | Major concerns | No concerns | No concerns | Very low |
| QLB: TAPB | 2 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| TAPB: WI | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | Some concerns | Low |
| Caudal: UG II-IHB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Systemic analgesia: LB II-IHB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Systemic analgesia: UG II-IHB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Systemic analgesia: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Systemic analgesia: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Control: UG II-IHB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Control: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Control: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| UG II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |

| UG II-IHB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | Major concerns | No concerns | Very low |
|-------------------------------|-------|----------------|----------|---------------|----------------|----------------|----------------|-----------|
| QLB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| | | | | | No concerns | No concerns | No concerns | Widderate |
| Number of patients requirin | | | 1 | _ | Some concome | Sama aanaama | No concome | Vortelow |
| Caudal: Systemic analgesia | 4 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Caudal block: LB II-IHB | | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Caudal: TAPB | 4 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Caudal block: WI | 4 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Systemic analgesia: QLB | 1 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| Systemic analgesia: WI | 1 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Control: LB II-IHB | 1 | Major concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Control: WI | 2 | Major concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| LB II-IHB: WI | 2 | Major concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| UG II-IHB: QLB | 2 | No concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| UG II-IHB: TAPB | 1 | No concerns | Low risk | No concerns | Major concerns | No concerns | Some concerns | Very low |
| QLB: TAPB | 1 | No concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Low |
| TAPB: WI | 2 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| Caudal: Control | 0 | Some concerns | Low risk | No concerns | No concerns | Major concerns | Major concerns | Very low |
| Caudal: UG II-IHB | 0 | No concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Caudal: QLB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: Control | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: LB II-IHB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: UG II-IHB | 0 | No concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: TAP | 0 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| Control: UG II-IHB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| | 0 | | Low risk | No concerns | No concerns | - | - | Very low |
| Control: QLB Control: TAPB | | Some concerns | | | | Major concerns | Major concerns | |
| | 0 | Some concerns | Low risk | No concerns | No concerns | Major concerns | Major concerns | Very low |
| LB II-IHB: UG II-IHB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| UG II-IHB: WI | 0 | No concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| QLB: WI | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | Major concerns | Very low |
| Postoperative pain score at (|)–2 h | T | T | T | 1 | 1 | T | T |
| Caudal: Control | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: LB II-IHB | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: Systemic analgesia | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: TAPB | 2 | Major concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Low |
| Caudal: WI | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Control: LB II-IHB | 2 | Major concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Very low |
| Control: Systemic analgesia | 2 | Major concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Very low |
| Control: WI | 4 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| LB II-IHB: Systemic analgesia | 4 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| LB II-IHB: WI | 3 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| QLB: TAPB | 1 | Some concerns | Low risk | Some concerns | No concerns | Some concerns | No concerns | Very low |
| Systemic analgesia: WI | 2 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Caudal: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Caudai: QLB Control: QLB | 0 | | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| - | | Some concerns | | | | | | |
| Control: TAPB | 0 | Major concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Low |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| QLB: Systemic analgesia | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| QLB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| Systemic analgesia: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| TAPB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Postoperative pain score at | 1–6 h | 1 | | 1 | 1 | 1 | 1 | 1 |
| Caudal: Control | 1 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| Caudal: LB II-IHB | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Some concerns | Very low |
| Caudal: TAPB | 3 | Major concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Caudal: WI | 1 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| | 1 | | 1 | + | + | <u> </u> | 4 | + |

| | | | | | | | | 11 |
|--|--|---|--|--|---|--|--|--|
| Control: WI | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| LB II-IHB: Systemic analgesia | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| LB II-IHB: WI | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| QLB: TAPB | 1 | Some concerns | Low risk | Some concerns | No concerns | Major concerns | Major concerns | Very low |
| Systemic analgesia: WI | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Caudal: QLB | 0 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | Major concerns | Very low |
| Caudal: Systemic analgesia | 0 | Some concerns | Low risk | No concerns | Some concerns | No concerns | Major concerns | Very low |
| Control: QLB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Control: Systemic analgesia | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| Control: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | Major concerns | Very low |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | Some concerns | No concerns | Major concerns | Very low |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| QLB: Systemic analgesia | 0 | Some concerns | Low risk | No concerns | Some concerns | No concerns | Major concerns | Very low |
| QLB: WI | 0 | Some concerns | Low risk | No concerns | Some concerns | No concerns | Major concerns | Very low |
| Systemic analgesia: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| TAPB: WI | 0 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Major concerns | Very low |
| | 0 | Some concerns | LOW HSK | No concerns | No concerns | Some concerns | wajor concerns | Very low |
| Postoperative pain score at 8 | | S | T | N | Net en l'estat | Not onelissible | Nat annlinghla | Net and is shite |
| Caudal: LB II-IHB | 1 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Caudal: TAPB | 2 | Major concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Caudal: WI | 1 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Control: WI | 1 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| LB II-IHB: WI | 1 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| QLB: TAPB | 1 | Some concerns | Low risk | Some concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Caudal: Control | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Caudal: QLB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Control: LB II-IHB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Control: QLB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Control: TAPB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| LB II-IHB: QLB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| LB II-IHB: TAPB | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| QLB: WI | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| TAPB: WI | 0 | Some concerns | Low risk | No concerns | Not applicable | Not applicable | Not applicable | Not applicable |
| Postoperative nausea and vo | miting du | ring the hospital s | stay and at home | | | | | |
| Caudal: Control | 2 | Some concerns | Low risk | No concerns | Some concerns | No concerns | No concerns | Low |
| Caudal: LB II-IHB | 3 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Caudal: UG II-IHB | 1 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Caudal: QLB | 1 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Caudal: Systemic opioids | 5 | Some concerns | Low risk | No concerns | No concerns | Some concerns | Some concerns | Very low |
| Caudal: TAPB | 5 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| Caudal: WI | 5 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| Control: LB II-IHB | 2 | Major concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Very low |
| Control: UG II-IHB | 1 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Control: Systemic opioids | 1 | Major concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
| Control: TAPB | 1 | • | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |
| | 1 | Some concerns | | | | | | |
| Control: WI | 2 | Some concerns | Low risk | No concerns | No concerns | Some concerns | No concerns | Low |
| LB II-IHB: Systemic opioids | 4 | Carrier | | | | No concerns | Some concerns | Low |
| LB II-IHB: WI | 4 | Some concerns | Low risk | No concerns | No concerns | C | N | ¥7 |
| | 4 3 | Some concerns | Low risk | No concerns | Some concerns | Some concerns | No concerns | Very low |
| QLB: TAPB | | Some concerns Some concerns | Low risk Low risk | No concerns No concerns | Some concerns Major concerns | No concerns | No concerns | Very low |
| Systemic opioids: WI | 3 1 1 | Some concerns Some concerns Some concerns | Low risk Low risk Low risk | No concerns No concerns No concerns | Some concerns Major concerns No concerns | No concerns Some concerns | No concerns No concerns | Very low Low |
| Systemic opioids: WI TAPB: WI | 3 1 1 2 | Some concerns Some concerns Some concerns Some concerns | Low risk Low risk Low risk Low risk | No concerns No concerns No concerns No concerns | Some concerns Major concerns No concerns Some concerns | No concerns Some concerns No concerns | No concerns No concerns Some concerns | Very low Low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB | 3 1 1 2 0 | Some concernsSome concernsSome concernsSome concernsSome concerns | Low risk Low risk Low risk Low risk Low risk | No concerns No concerns No concerns No concerns No concerns | Some concerns Major concerns No concerns Some concerns Major concerns | No concernsSome concernsNo concernsNo concerns | No concerns No concerns Some concerns No concerns | Very low Low Very low Very low |
| Systemic opioids: WI TAPB: WI | 3 1 1 2 | Some concerns Some concerns Some concerns Some concerns | Low risk Low risk Low risk Low risk | No concerns No concerns No concerns No concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns | No concerns Some concerns No concerns | No concerns No concerns Some concerns | Very low Low Very low Very low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB | 3 1 1 2 0 | Some concernsSome concernsSome concernsSome concernsSome concerns | Low risk Low risk Low risk Low risk Low risk | No concerns No concerns No concerns No concerns No concerns | Some concerns Major concerns No concerns Some concerns Major concerns | No concernsSome concernsNo concernsNo concerns | No concerns No concerns Some concerns No concerns | Very low Low Very low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB LB II-IHB: UG II-IHB | 3 1 1 2 0 0 | Some concernsSome concernsSome concernsSome concernsSome concernsSome concerns | Low risk Low risk Low risk Low risk Low risk Low risk | No concerns No concerns No concerns No concerns No concerns No concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns | No concernsSome concernsNo concernsNo concernsNo concerns | No concerns No concerns Some concerns No concerns No concerns | Very low Low Very low Very low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB LB II-IHB: UG II-IHB LB II-IHB: QLB | 3 1 1 2 0 0 0 0 | Some concernsSome concernsSome concernsSome concernsSome concernsSome concernsSome concernsSome concerns | Low risk Low risk Low risk Low risk Low risk Low risk Low risk | No concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns Major concerns | No concerns Some concerns No concerns No concerns No concerns | No concernsNo concernsSome concernsNo concernsNo concernsNo concernsNo concerns | Very low Low Very low Very low Very low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB LB II-IHB: UG II-IHB LB II-IHB: QLB LB II-IHB: TAPB | 3 1 1 2 0 0 0 0 0 0 | Some concernsSome concernsSome concernsSome concernsSome concernsSome concernsSome concernsSome concernsSome concerns | Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk | No concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns Major concerns Some concerns | No concerns Some concerns No concerns No concerns No concerns No concerns | No concernsNo concernsSome concernsNo concernsNo concernsNo concernsNo concernsNo concerns | Very low Low Very low Very low Very low Very low Low |
| Systemic opioids: WI TAPB: WI Control: QLB LB II-IHB: UG II-IHB LB II-IHB: QLB LB II-IHB: TAPB UG II-IHB: QLB | 3 1 1 2 0 0 0 0 0 0 0 0 | Some concernsSome concerns | Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk | No concernsNo concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns Some concerns Some concerns | No concerns Some concerns No concerns No concerns No concerns No concerns No concerns | No concernsNo concernsSome concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concerns | Very low Low Very low Very low Very low Very low Low Very low |
| Systemic opioids: WI TAPB: WI Control: QLB LB II-IHB: UG II-IHB LB II-IHB: QLB LB II-IHB: TAPB UG II-IHB: QLB UG II-IHB: Systemic opioids | 3 1 1 2 0 0 0 0 0 0 0 0 0 0 | Some concernsSome concerns | Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk | No concernsNo concerns | Some concerns Major concerns No concerns Some concerns Major concerns Major concerns Some concerns Some concerns Major concerns Major concerns | No concernsSome concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concerns | No concernsNo concernsSome concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concernsNo concerns | Very low Low Very low Very low Very low Very low Low Very low Very low |

| QLB: WI | 0 | Some concerns | Low risk | No concerns | Major concerns | No concerns | No concerns | Very low |
|------------------------|---|---------------|----------|-------------|----------------|-------------|-------------|----------|
| Systemic opioids: TAPB | 0 | Some concerns | Low risk | No concerns | No concerns | No concerns | No concerns | Moderate |



Section 6. Network league table of the secondary outcomes

Number of patients requiring opioid rescue analgesics during the hospital stay

| QLB | | | | | | | |
|--------------|--------------|--------------|---------------|--------------|--------------|--------------|---------|
| 0.76 | ТАРВ |] | | | | | |
| (0.10, 5.78) | | | | | | | |
| 0.48 | 0.64 | Caudal | | | | | |
| (0.06, 4.05) | (0.18, 2.30) | block | | | | | |
| 0.42 | 0.56 | 0.88 | UG II-IHB | | | | |
| (0.06, 2.81) | (0.06, 5.29) | (0.08, 9.83) | | | | | |
| 0.33 | 0.43 | 0.67 | 0.77 | LB II-IHB | | | |
| (0.02, 5.58) | (0.04, 4.16) | (0.09, 4.99) | (0.04, 16.36) | | | | |
| 0.21 | 0.28 | 0.44 | 0.50 | 0.65 | WI | | |
| (0.02, 2.11) | (0.06, 1.30) | (0.14, 1.40) | (0.04, 6.49) | (0.11, 3.96) | | | |
| 0.14 | 0.19 | 0.30 | 0.34 | 0.44 | 0.68 | Systemic | |
| (0.02, 1.19) | (0.03, 1.04) | (0.08, 1.11) | (0.03, 4.08) | (0.04, 4.46) | (0.14, 3.37) | analgesia | |
| 0.04 | 0.06 | 0.09 | 0.10 | 0.14 | 0.21 | 0.31 | Control |
| (0.00, 0.79) | (0.01, 0.60) | (0.01, 0.74) | (0.00, 2.31) | (0.02, 1.14) | (0.04, 1.24) | (0.03, 3.24) | |

[Odds ratio (95% Confidence interval)]

Postoperative pain score at 0-2 h [Standardised mean difference (95% Confidence interval)]

| QLB | | | | | | |
|----------------|----------------|----------------|----------------|----------------|----------------|---------|
| -0.79 | ТАРВ | | | | | |
| (-1.89, 0.31) | | | | | | |
| -1.39 | -0.60 | Caudal block | | | | |
| (-2.72, -0.05) | (-1.36, 0.16) | | | | | |
| -1.84 | -1.05 | -0.45 | LB II-IHB | | | |
| (-3.27, -0.40) | (-1.97, -0.13) | (-0.97, 0.07) | | | _ | |
| -1.97 | -1.18 | -0.58 | -0.13 | WI | | |
| (-3.40, -0.54) | (-2.10, -0.27) | (-1.10, -0.07) | (-0.59, 0.32) | | | _ |
| -2.03 | -1.24 | -0.64 | -0.19 | -0.05 | Systemic | |
| (-3.46, -0.59) | (-2.16, -0.31) | (-1.17, -0.11) | (-0.62, 0.24) | (-0.52, 0.41) | analgesia | |
| -3.16 | -2.37 | -1.77 | -1.32 | -1.19 | -1.13 | Control |
| (-4.60, -1.71) | (-3.30, -1.43) | (-2.32, -1.22) | (-1.83, -0.81) | (-1.64, -0.73) | (-1.65, -0.61) | |

Postoperative pain score at 4–6 h [Standardised mean difference (95% Confidence interval)]

| TAPB | | | | | | |
|----------------|----------------|----------------|----------------|----------------|----------------|---------|
| 0.17 | QLB |] | | | | |
| (-1.43, 1.77) | | | | | | |
| -0.52 | -0.69 | Caudal block | | | | |
| (-1.45, 0.40) | (-2.54, 1.16) | | | | | |
| -1.42 | -1.59 | -0.90 | WI | | | |
| (-2.85, 0.00) | (-3.73, 0.55) | (-1.99, 0.18) | | | | |
| -1.42 | -1.59 | -0.90 | 0.00 | LB II-IHB | | |
| (-2.78, -0.06) | (-3.69, 0.51) | (-1.90, 0.10) | (-0.86, 0.87) | | | |
| -1.58 | -1.75 | -1.06 | -0.16 | -0.16 | Systemic | |
| (-3.12, -0.04) | (-3.97, 0.47) | (-2.29, 0.17) | (-1.06, 0.74) | (-1.06, 0.74) | analgesia | |
| -3.00 | -3.16 | -2.47 | -1.57 | -1.57 | -1.41 | Control |
| (-4.49, -1.51) | (-5.35, -0.98) | (-3.64, -1.30) | (-2.55, -0.59) | (-2.65, -0.50) | (-2.64, -0.19) | |

Postoperative pain score at 8–12 h [Standardised mean difference (95% Confidence interval)]


| QLB | | | | | |
|-----------------|-----------------|----------------|----------------|----------------|---------|
| | | 1 | | | |
| -0.72 | TAPB | | | | |
| (-1.72, 0.28) | | | _ | | |
| -1.12 | -0.40 | LB II-IHB | | | |
| (-2.70, 0.46) | (-1.61, 0.82) | | | _ | |
| -1.25 | -0.53 | -0.13 | Caudal block | | |
| (-2.47, -0.02) | (-1.23, 0.18) | (-1.12, 0.86) | | | _ |
| -1.56 | -0.84 | -0.44 | -0.31 | WI | |
| (-3.14, 0.01) | (-2.06, 0.38) | (-1.44, 0.55) | (-1.31, 0.68) | | |
| -8.94 | -8.21 | -7.82 | -7.69 | -7.37 | Control |
| (-11.06, -6.82) | (-10.08, -6.35) | (-9.55, -6.09) | (-9.42, -5.96) | (-8.79, -5.96) | |

Postoperative nausea and vomiting during the hospital stay and at home

[Odds ratio (95% Confidence interval)]

| ТАРВ | | | | | | | |
|---------------|--------------|--------------|--------------|--------------|---------------|--------------|----------|
| 1.76 | QLB |] | | | | | |
| (0.06, 52.02) | | | | | | | |
| 0.54 | 0.31 | WI | | | | | |
| (0.24, 1.22) | (0.01, 9.30) | | | | | | |
| 0.53 | 0.30 | 0.98 | LB II-IHB | | | | |
| (0.22, 1.29) | (0.01, 9.21) | (0.50, 1.91) | | | | | |
| 0.52 | 0.30 | 0.96 | 0.98 | Caudal block | | | |
| (0.29, 0.95) | (0.01, 8.34) | (0.49, 1.87) | (0.47, 2.02) | | | | |
| 0.24 | 0.14 | 0.44 | 0.45 | 0.46 | UG II-IHB | | |
| (0.02, 3.39) | (0.00, 9.23) | (0.03, 6.33) | (0.03, 6.56) | (0.03, 6.07) | | | |
| 0.28 | 0.16 | 0.52 | 0.53 | 0.54 | 1.19 | Control | |
| (0.12, 0.67) | (0.01, 4.88) | (0.24, 1.14) | (0.24, 1.18) | (0.26, 1.11) | (0.08, 17.42) | | |
| 0.13 | 0.07 | 0.24 | 0.24 | 0.25 | 0.55 | 0.46 | Systemic |
| (0.05, 0.37) | (0.00, 2.35) | (0.09, 0.61) | (0.11, 0.53) | (0.10, 0.62) | (0.04, 8.50) | (0.17, 1.22) | opioids |

Section 7. Summary of the sensitivity analysis on the primary outcome based on studies with or without orchidopexies.



| Studies with orchidopexies | Caudal block | | | | | | | |
|-----------------------------------|----------------------|--------------------|--------------------|--------------------|---------------------|-----------------------|-----------------------|-----------|
| (hours) [MD (CI)] | 0.46 (-2.42, 3.33) | QLB | | | | | | |
| | 0.56 (-2.95, 4.07) | 0.10 (-4.44, 4.64) | UG II-IHB | | | | | |
| | 0.63 (-1.13, 2.40) | 0.17 (-2.73, 3.08) | 0.07 (-3.86, 4.00) | TAPB | | | | |
| | 1.54 (-3.30, 6.38) | 1.08 (-4.22, 6.38) | 0.98 (-5.00, 6.96) | 0.91 (-4.18, 5.99) | WI | | | |
| | 3.85 (0.86, 6.83) | 3.39 (0.18, 6.60) | 3.29 (-1.33, 7.90) | 3.21 (-0.07, 6.50) | 2.31 (-2.49, 7.10) | Systemic analgesia | | |
| | 4.07 (0.67, 7.47) | 3.61 (-0.42, 7.63) | 3.51 (-1.38, 8.40) | 3.44 (-0.31, 7.18) | 2.53 (-0.92, 5.98) | 0.22 (-3.11, 3.56) | Control | |
| | 5.50 (0.63, 10.36) | 5.04 (0.03, 10.04) | 4.94 (-1.07,10.94) | 4.86 (-0.19, 9.92) | 3.96 (-2.19, 10.10) | 1.65 (-2.20, 5.50) | 1.43 (-3.66, 6.52) | LB II-IHB |
| Studies without orchidopexies | QLB | | | | | | | |
| (inguinal hernia | 4.54 (2.52, 6.57) | UG II-IHB | | | | | | |
| repair only) (hours) [MD (CI)] | 4.60 (2.37, 6.84) | 0.06 (-1.75, 1.87) | TAPB | | | | | |
| | 8.87 (6.54, 11.20) | 4.32 (2.55, 6.10) | 4.27 (3.07, 5.46) | Caudal block | | | | |
| | 10.02 (7.00, 13.03) | 5.47 (2.87, 8.08) | 5.41 (3.17, 7.65) | 1.15 (-0.77, 3.06) | LB II-IHB | | | |
| | 10.27 (7.70, 12.83) | 5.72 (3.64, 7.81) | 5.66 (4.10, 7.23) | 1.40 (0.24, 2.56) | 0.25 (-1.87, 2.37) | WI | | |
| | 10.79 (8.22, 13.36) | 6.24 (4.16, 8.33) | 6.18 (4.59, 7.78) | 1.92 (0.80, 3.04) | 0.77 (-1.20, 2.75) | 0.52 (-0.64, 1.68) | Systemic analgesia | |
| | 13.46 (10.53, 16.38) | 8.91 (6.40, 11.43) | 8.85 (6.73, 10.97) | 4.59 (2.78, 6.39) | 3.44 (0.86, 6.02) | 3.19 (1.42, 4.96) | 2.67 (0.71, 4.62) | Control |

CI, confidence interval; II-IHB, ilioinguinal-iliohypogastric block; LB, landmark-based; MD, mean difference; OR, odds ratio; QLB, quadratus lumborum block; TAPB, transversus


abdominis plane block; UG, ultrasound-guided; WI, wound infiltration.


a. Control: comparison group that received only the standard care of the corresponding intervention group.


b. Systemic analgesia: comparison group that received additional systemic analgesic to the standard care of the corresponding intervention group.

c. The statistically significant results are in bold type.

Section 8. Summary of the sensitivity analysis on the primary outcome by excluding high risk of bias studies










Section 10. Netsplit for the primary and secondary outcomes

| me to the first rescue anal | gesic after surger | ·y | | Number of patients requiring rescue analgesics after surgery | |
|--|--|---|--|---|--|
| | | | | | |
| comparison | | | p-value | comparison k prop nma direct indir. RoR z p-value | |
| | | 801 5.4478 -2.2177 -1.17 | 0.2419 | Caudal block:Control 1 0.30 0.1213 0.0941 0.1349 0.6977 -0.31 0.7560 | |
| | | 100 3.8101 -3.8201 -1.61 100 -5.5266 8.4366 3.59 | 0.1064 0.0003 | Caudal block:LB II-IHB 3 0.44 0.4797 1.0928 0.2499 4.3736 1.64 0.1010 | |
| udal block:Systemic analgesia | | | 0.4547 | Caudal block:QLB 2 0.56 8.6930 4.6466 19.2855 0.2409 -1.22 0.2238 | |
| | | 553 -4.3988 3.1335 1.92 | 0.0546 | Caudal block:Systemic analgesia 8 0.86 0.3235 0.4066 0.0831 4.8942 1.59 0.1108 Caudal block:TAPB 6 0.76 4.0336 2.4143 20.9686 0.1151 -2.02 0.0439 | |
| Caudal block:UG II-IHB | 2 0.61 -1.0324 -1.04 | 81 -1.0079 -0.0402 -0.02 | 0.9838 | Caudal block:UG II-IHB 1 0.41 2.1470 1.4167 2.8503 0.4970 -0.52 0.602 | |
| | | 077 1.9978 -0.0901 -0.06 | 0.9531 | Caudal block:WI 5 0.58 0.4957 0.5237 0.4595 1.1399 0.18 0.8552 | |
| LB II-IHB:Control | | . 2.0816 | | LB II-IHB:Control 1 0.32 0.2528 0.4318 0.1967 2.1953 0.65 0.518 | |
| QLB:Control | | . 7.6575 | | QLB:Control 0 0 0.0139 . 0.0139 | |
| Systemic analgesia:Control TAPB:Control | | . 6.0259 | 0.3021 | Systemic analgesia:Control 1 0.34 0.3749 0.2941 0.4241 0.6936 -0.30 0.761 TAPB:Control 0 0 0.0301 . 0.0301 . | |
| UG II-IHB:Control | | . 5.2582 | | UG II-IHB:Control 0 0 0.0565 . 0.0565 | |
| | 2 0.56 2.2693 3.60 | | 0.0984 | WI:Control 3 0.69 0.2446 0.2630 0.2080 1.2642 0.23 0.820 | |
| LB II-IHB:QLB | | 5.5759 | | LB II-IHB:QLB 0 0 18.1221 . 18.1221 | |
| LB II-IHB:Systemic analgesia | 2 0.66 0.0145 -1.27 | 792 2.5409 -3.8201 -1.61 | 0.1064 | LB II-IHB:Systemic analgesia 0 0 0.6743 . 0.6743 | |
| LB II-IHB:TAPB | | 3.9443 | | LB II-IHB:TAPB 0 0 8.4087 . 8.4087 | |
| LB II-IHB:UG II-IHB | | 3.1766 | • | LB II-IHB:UG II-IHB 1 0.44 4.4758 10.4444 2.2964 4.5482 1.08 0.279 | |
| LB II-IHB:WI | | 0.1877 | | LB II-IHB:WI 6 0.80 | |
| | | 000 6.0191 -1.5191 -0.60 115 -0.9805 4.1220 1.95 | 0.5474 0.0516 | QLB:Systemic undigesta 0 0 0.0572 . 0.0572 . 0.0572 . 0.27 0.790 | |
| | | 066 0.0564 3.7503 1.63 | 0.1029 | QLB:UG II-IHB 1 0.45 0.2470 0.1556 0.3628 0.4287 -0.57 0.568 | |
| QLB:00 II IIB QLB:WI | | . 5.3882 | 0.1025 | QLB:WI 0 0 0.0570 . 0.0570 | |
| Systemic analgesia:TAPB | | 3.9588 | | Systemic analgesia:TAPB 0 0 12.4693 . 12.4693 | |
| Systemic analgesia:UG II-IHB | | 3.1911 | | Systemic analgesia:UG II-IHB 0 0 6.6372 . 6.6372 | |
| Systemic analgesia:WI | 3 0.60 -0.2021 -1.40 | 508 1.6671 -3.1279 -1.96 | 0.0504 | Systemic analgesia:WI 2 0.38 1.5324 4.0331 0.8375 4.8155 1.79 0.074 | |
| TAPB:UG II-IHB | | 000 1.9836 -3.9836 -1.77 | 0.0764 | TAPB:UG II-IHB 0 0 0.5323 . 0.5323 TAPB:WI 2 0.21 0.1229 0.0114 0.2299 0.0494 -2.26 0.024 | |
| | 1 0.18 3.7567 12.30 | 000 1.8463 10.4537 4.38 | < 0.0001 | UG II-IHB:WI 0 0 0.2309 . 0.2309 | |
| UG II-IHB:WI | 0 0 2.9889 | . 2.9889 | al stay | | |
| | 0 0 2.9889 | | al stay | Postoperative pain score at 0–2 h | |
| UG II-IHB:WI | 0 0 2.9889 opioid rescue analg | gesics during the hospita | al stay | | |
| UG II-IHB:WI | 0 0 2.9889 Opioid rescue analg k prop nma direct | gesics during the hospita indir. RoR z p 0.0919 | -value | Postoperative pain score at 0–2 h | |
| UG II-IHB:WI mber of patients requiring of comparison Caudal block:Control Caudal block:LB II-IHB | <pre>0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936</pre> | gesics during the hospita indir. RoR z 0.0919 . . 0.2593 30.4426 1.50 | -value | Postoperative pain score at 0-2 h comparison k prop nma direct indir. Diff z p-va | |
| UG II-IHB:WI Imber of patients requiring o comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:QLB | <pre>0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 .</pre> | gesics during the hospita indir. RoR z 0.0919 . . 0.2593 30.4426 1.50 2.0694 . . | -value 0.1336 | comparison k prop nma direct indir. Diff z p-val Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 | |
| UG II-IHB:WI mber of patients requiring of comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia | <pre>0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014</pre> | indir. RoR z p [.] 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (| -value 0.1336 0.1869 | comparison k prop nma direct indir. Diff z p-val Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 | |
| UG II-IHB:WI mmber of patients requiring of Caudal block:Control Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (| -value 0.1336 0.1869 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:QLB 0 0 1.3871 . . . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB Caudal block:UG II-IHB | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (0.8791 | -value 0.1336 0.1869 0.5629 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:QLB 0 0 1.3871 . . . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB Caudal block:UG II-IHB Caudal block:WI | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (0.8791 0.1790 3.3564 0.89 (| -value 0.1336 0.1869 0.5629 0.3713 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.11 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:QLB 0 0 1.3871 . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB Caudal block:UG II-IHB Caudal block:WI | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (0.8791 0.1790 3.3564 0.89 (| -value 0.1336 0.1869 0.5629 0.3713 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.11 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:QLB 0 0 1.3871 . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (0.8791 0.1790 3.3564 0.89 (0.0115 37.4181 1.56 (| -value 0.1336 0.1869 0.5629 0.3713 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.6 Caudal block:TAPB 2 1.00 0.5983 0.5983 . . . Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.7 | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control Systemic analgesia:Control TAPB:Control | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 | -value 0.1336 0.1869 0.5629 0.3713 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:QLB 0 1.3871 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.66 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.66 Caudal block:Systemic analgesia 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.70 | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:TAPB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control Systemic analgesia:Control TAPB:Control UG II-IHB:Control | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:QLB 0 0 1.3871 . 1.3871 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.60 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.77 LB II-IHB:Control 2 0.43 -1.3198 -1.4128 -1.2486 -0.1642 -0.31 0.77 QLB:Control 0 0 -3.15583.1558 | |
| UG II-IHB:WI mber of patients requiring of Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control Systemic analgesia:Control TAPB:Control UG II-IHB:Control WI:Control | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:QLB 0 0 1.3871 . 1.3871 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.6 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.7 LB II-IHB:Control 2 0.43 -1.3198 -1.4128 -1.2486 -0.1642 -0.31 0.7 QLB:Control 0 0 -3.1558 3.1558 Systemic analgesia:Control 2 0.41 -1.1303 -0.9687 -1.2422 0.2735 0.51 0.6 | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control Systemic analgesia:Control TAPB:Control UG II-IHB:Control WI:Control LB II-IHB:QLB | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 3.0726 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:QLB 0 0 1.3871 . 1.3871 . Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.6 Caudal block:TAPB 2 1.00 0.5983 0.5983 . Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.7 LB II-IHB:Control 2 0.43 -1.3198 -1.4128 -1.2486 -0.1642 -0.31 0.7 QLB:Control 0 0 -3.1558 . Systemic analgesia:Control 2 0.41 -1.1303 -0.9687 -1.2422 0.2735 0.51 0.6 TAPB:Control 0 0 -2.3671 . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG III-IHB Caudal block:UG II-IHB Caudal block:UG III-IHB C | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 3.0726 0.4442 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | Comparison k prop nma direct indir. Diff z p-val Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1. Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1. Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II 0 1.3871 . | |
| UG II-IHB:WI mber of patients requiring of Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:QLB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control WI:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:TAPB | 0 0 2.9889 opioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . | indir. RoR z p 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 3.0726 0.4442 0.4442 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | Comparison k prop nma direct indir. Diff z p-val Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1. Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.60 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.60 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.7 LB II-IHB:Control 2 0.43 -1.3198 -1.4128 -1.2486 -0.1642 -0.31 0.7 QLB:Control 0 0 -3.1558 3.1558 Systemic analgesia:Control 2 0.41 -1.1303 -0.9687 -1.2422 0.2735 0.51 0.6 TAPB:Control 0 0 -2.3671 2.3671 WI:Control 4 0.65 -1.1850 -0.9927 -1.5464 0.5538 1.15 0.21 LB II-IHB:QLB 0 0 1.8360 | |
| UG II-IHB:WI mber of patients requiring of Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:VG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control WI:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:TAPB LB II-IHB:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 3.0726 0.4442 2.3279 1.3053 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 | Comparison k prop nma direct indirect indifted indirect < | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:TAPB LB II-IHB:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 | indir. RoR z p- 0.0919 . . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 3.0726 . . . 0.4442 . . . 1.3053 . . . | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 | Comparison k prop nma direct indirect indiffere indirect | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 0 2.0694 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 0 3.0726 0.4442 2.3279 1.3053 0.2933 2.9939 0.53 0 0.0082 172.5108 2.38 0 5.6131 0.0257 -1.76 0 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 | Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.11 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II -IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II -IHB 2 0.44 -0.489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB II - IHB 2 0.44 -0.489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:QLB 0 1.3871 . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.56 0.1446 1.4167 | indir. RoR z p- 0.0919 0.2593 30.4426 1.50 (2.0694 2.1173 0.0951 -1.32 (2.8636 0.4313 -0.58 (0.8791 0.1790 3.3564 0.89 (0.0115 37.4181 1.56 (0.0444 0.3072 0.0586 0.1046 5.8276 0.0283 -0.99 (3.0726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.4442 0.30726 0.30726 0.4442 0.30726 0.30726 0.30726 0.30726 0.3086 0.3086 0.3086 0.3086 0.308 0.308 0.308 0.308 0.444 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 0.308 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 | Comparison k prop nma direct indirect indit indirect <th< td=""></th<> | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control Systemic analgesia:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 . . . 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 3.0726 . . . 0.23279 . . . 1.3053 . . . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 3067.7718 0.0001 -2.38 0 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 | Postoperative pain score at 0–2 h comparison k prop nma direct indirect indirect <th c<="" td=""></th> | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:UG Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB QLB:WI Systemic analgesia:TAPB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . 0 0 5.2406 . | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 . . . 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 0.3072 . . . 0.1046 . . . 0.3072 . . . 0.1046 . . . 0.1046 . . . 0.2933 2.9939 0.53 . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 5.6131 0.0257 -1.76 0 3067.7718 0.0001 -2.38 0 0.21 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 | Postoperative pain score at 0–2 h Comparison k prop nma direct indir. Diff z p-va Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.1 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.4 Caudal block:LB 0 0 1.3871 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.6 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.6 Caudal block:WI 2 0.44 -0.5837 -0.5031 -0.6480 0.1449 0.27 0.7 LB II-IHB:Control 2 0.43 -1.3198 -1.4128 -1.2426 -0.2353 . . QLB:Control 0 0 -3.1558 VII:Control 4 0.65 | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control QLB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB QLB:WI Systemic analgesia:TAPB Systemic analgesia:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . 0 0 5.2406 . 0 0 2.9384 . | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.1790 3.3564 0.89 0 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 2.3279 . . . 1.3053 . . . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.2119 . . . 5.2406 . . . 2.9384 . . . | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 0.0173 | Comparison k prop nma direct indirect indirect <th colspan<="" td=""></th> | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control LB II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB QLB:WI Systemic analgesia:TAPB Systemic analgesia:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . 0 0 5.2406 . 0 0 2.9384 . 1 0.37 1.4655 3.7632 | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.1790 3.3564 0.89 0 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 2.3279 . . . 1.3053 . . . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.2119 . . . 5.2406 . . . 0.8454 4.4512 0.88 0 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.5958 0.0173 0.0788 0.0173 0.0788 0.0173 | Postoperative pain score at 0–2 h comparison k prop nma direct indir. Diff z p-val Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.12 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.66 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:TAPB 2 1.00 0.5983 0.5983 . | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB Systemic analgesia:CII-IHB Systemic analgesia:UG II-IHB Systemic analgesia:WI TAPB:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . 0 0 5.2406 . 0 0 2.9384 . 1 0.37 1.4655 3.7632 1 0.73 0.5607 2.2698 | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 . . . 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0444 . . . 0.3072 . . . 0.1046 . . . 2.3279 . . . 1.3053 . . . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.2119 . . . 5.2406 . . . 2.9384 0.8454 4.4512 0.88 0 . | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.3232 0.5958 0.0173 0.0788 0.0173 0.0788 0.0173 | Comparison k prop nma direct indirect indidirect indididirect | |
| UG II-IHB:WI comparison Caudal block:Control Caudal block:LB II-IHB Caudal block:LB II-IHB Caudal block:Systemic analgesia Caudal block:Systemic analgesia Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:UG II-IHB Caudal block:WI LB II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:Control UG II-IHB:QLB LB II-IHB:Systemic analgesia LB II-IHB:WI QLB:Systemic analgesia QLB:TAPB QLB:UG II-IHB Systemic analgesia:CII-IHB Systemic analgesia:UG II-IHB Systemic analgesia:WI TAPB:UG II-IHB | 0 0 2.9889 ppioid rescue analg k prop nma direct 0 0 0.0919 . 1 0.28 0.6735 7.8936 0 0 2.0694 . 4 0.83 0.2992 0.2014 4 0.72 1.5679 1.2352 0 0 0.8791 . 4 0.74 0.4385 0.6007 1 0.68 0.1365 0.4318 0 0 0.0444 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 0.4442 . 0 0 0.3072 . 0 0 0.0586 . 0 0 0.1046 . 2 0.93 0.2096 0.1648 0 0 3.0726 . 0 0 0.4442 . 0 0 2.3279 . 0 0 1.3053 . 2 0.73 0.6510 0.8781 1 0.55 0.7576 0.1444 2 0.94 0.4248 0.2351 0 0 0.2119 . 0 0 5.2406 . 0 0 2.9384 . 1 0.37 1.4655 3.7632 1 0.73 0.5607 2.2698 2 0.33 0.2796 0.0172 | indir. RoR z p- 0.0919 . . 0.2593 30.4426 1.50 0 2.0694 . . . 2.1173 0.0951 -1.32 0 2.8636 0.4313 -0.58 0 0.8791 . . . 0.1790 3.3564 0.89 0 0.0115 37.4181 1.56 0 0.0586 . . . 0.1046 . . . 2.3279 . . . 1.3053 . . . 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.0082 172.5108 2.38 0 0.2119 5.2406 0.8454 4.4512 0.88 0 0.0124 182.7764 2.02 0 | -value 0.1336 0.1869 0.5629 0.3713 0.1195 0.3232 0.3232 0.5958 0.0173 0.0788 0.0173 0.0788 0.0173 | Postoperative pain score at 0–2 h Comparison k prop nma direct indir. Diff z p-vai Caudal block:Control 2 0.42 -1.7687 -2.2820 -1.4046 -0.8774 -1.55 0.13 Caudal block:LB II-IHB 2 0.44 -0.4489 -0.2387 -0.6153 0.3767 0.70 0.44 Caudal block:Systemic analgesia 2 0.41 -0.6384 -0.4798 -0.7499 0.2701 0.49 0.63 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:TAPB 2 1.00 0.5983 0.5983 Caudal block:TAPB 2 1.00 0.5983 0.5983 . <td< td=""></td<> | |


| Candol block:18 11-18 2 0.76 - 0.3085 - 0.437 - 3.383 3.200 2 4.77 0.075 Candol block:18 0 0 0.6889 - 0.1788 - 0.772 - 0.728 - 0.728 - 0.688 - 0.6898 - 0.1788 - 0.1 | ostoperative pain score at 4–6 h | Postoperative pain score at 8–12 h |
|--|--|---|
| comparison k prop nma direct indir. RoR z p-value Caudal block:Control 4 0.54 0.5422 0.9658 0.2751 3.5103 1.70 0.0888 Caudal block:UB II-1HB 3 0.40 1.0222 0.7085 1.3998 0.5409 -0.82 0.4144 Caudal block:UB II 1.00 3.3673 3.3673 | Caudal block:Control 1 0.41 -2.4738 -5.1597 -0.6196 -4.5400 -3.74 0.0002 Caudal block:LB II-IHB 2 0.76 -0.9006 -0.1476 -3.3487 3.2010 2.67 0.0076 Caudal block:QLB 0 0 0.6889 .0.6889 audal block:Systemic analgesia 0 0 -1.06131.0613 Caudal block:TAPB 3 1.00 0.5225 0.5225 Caudal block:WI 1 0.46 -0.9016 0.4436 -2.0517 2.4953 2.24 0.0248 LB II-IHB:Control 1 0.46 -1.5732 -0.4336 -2.5562 2.1226 1.92 0.0542 QLB:Control 0 0 -3.16273.1627 Systemic analgesia:Control 0 0 -1.41251.4125 MI:Control 2 0.77 -1.5722 -0.7260 -4.4661 3.7402 3.13 0.0017 LB II-IHB:QLB 0 0 1.5895 MI:Control 2 0.77 -1.5722 LB II-IHB:QLB 0 0 1.4232 LB II-IHB:TAPB 0 0 1.4232 LB II-IHB:TAPB 0 0 1.4232 LB II-IHB:WI 2 0.59 -0.0010 0.0473 -0.0707 0.1180 0.13 0.8954 QLB:Systemic analgesia 0 0 -1.7502 QLB:TAPB 1 1.00 -0.1664 -0.1664 QLB:TAPB 1 1.00 0.15838 Systemic analgesia:TAPB 0 0 1.5838 Systemic analgesia:WI 2 0.65 0.1597 0.3118 -0.1229 0.4347 0.45 0.6515 | Caudal block:Control 0 0 -7.68757.6875 Caudal block:LB II-IHB 1 1.00 0.1305 0.1305 Caudal block:QLB 0 0 1.2491 . 1.2491 Caudal block:TAPB 2 1.00 0.5265 0.5265 Caudal block:WI 1 1.00 -0.3131 -0.3131 LB II-IHB:Control 0 0 -7.81807.8180 QLB:Control 0 0 -8.93668.9366 TAPB:Control 0 0 -8.21408.2140 WI:Control 1 1.00 -7.3744 -7.3744 LB II-IHB:QLB 0 0 1.1186 . 1.1186 LB II-IHB:TAPB 0 0 0.3960 . 0.3960 LB II-IHB:WI 1 1.00 -0.4436 -0.4436 QLB:TAPB 1 1.00 -0.7226 -0.7226 QLB:WI 0 0 -1.56221.5622 |
| Caudal block:Systemic opioids 2 0.30 0.497 0.3330 0.2213 1.5048 0.440 0.6896 Caudal block:TAPB 5 0.81 1.9172 1.6936 3.2665 0.5185 -0.84 0.4012 Caudal block:TAPB 5 0.8455 0.4565 - - - Caudal block:TAPB 1 1.09 4.5655 0.4565 - - - Caudal block:TAPB 1 1.09 1.6250 - - - - Caudal block:TAPB 1 0.4565 0.4562 -0.76 0.4502 0.7818 Control:QLB 0 6.2110 -6.2110 - - - Control:TAPB 1 0.83 3.556 1.2429 0.3613 0.7576 Control:TAPB 1 0.83 3.576 1.557 4.2485 0.3616 - 8 0.3770 Control:WI 2 0.32 1.9258 5.7656 1.557 - - - LB II-IHB:Systemic opioids 0 0.3242 0.30 0.51 | comparison k prop nma direct indir. RoR z p-value Caudal block:Control 4 0.54 0.5422 0.9658 0.2751 3.5103 1.70 0.0888 Caudal block:LB II-IHB 3 0.40 1.0222 0.7085 1.3098 0.5409 -0.82 0.4144 | - |
| Control:QLB 0 6.2110 6.2110 . . Control:Systemic opioids 1 0.33 0.4605 1.0000 0.3153 3.1714 1.09 0.2736 Control:TAPB 1 0.18 3.5363 1.5556 4.2485 0.3661 -0.88 0.3770 Control:VG II-IHB 0 0.8420 . 8.420 . . . Control:WI 2 0.32 1.9258 5.7656 1.1597 4.9716 1.86 0.0627 LB II-HB:QLB 0 0.2442 3.2942 . . . LB II-HB:Systemic opioids 4 0.79 0.2443 0.2139 0.5576 . . LB II-HB:Systemic opioids 4 0.79 0.2443 0.2139 0.557 . LB II-HB:Systemic opioids 4 0.79 0.4466 . . . LB II-HB:WI 3 0.65 1.0214 1.1012 0.878 1.2404 0.30 0.7639 QLB:UG II-HB <td>Caudal block:Systemic opioids 2 0.30 0.2497 0.3330 0.2213 1.5048 0.40 0.6896 Caudal block:TAPB 5 0.81 1.9172 1.6936 3.2665 0.5185 -0.84 0.4012 Caudal block:UG II-IHB 1 1.00 0.4565 0.4565 Caudal block:WI 4 0.46 1.0441 0.7900 1.3249 0.5962 -0.76 0.4502</td> <td></td> | Caudal block:Systemic opioids 2 0.30 0.2497 0.3330 0.2213 1.5048 0.40 0.6896 Caudal block:TAPB 5 0.81 1.9172 1.6936 3.2665 0.5185 -0.84 0.4012 Caudal block:UG II-IHB 1 1.00 0.4565 0.4565 Caudal block:WI 4 0.46 1.0441 0.7900 1.3249 0.5962 -0.76 0.4502 | |
| LB II-IHB:QLB 0 0 3.2942 . 3.2942 LB II-IHB:Systemic opioids 4 0.79 0.2443 0.2139 0.4058 0.5272 -0.65 0.5137 LB II-IHB:TAPB 0 0 1.8756 . 1.8756 LB II-IHB:UG II-IHB 0 0 0.4466 . 0.4466 LB II-IHB:WI 3 0.65 1.0214 1.1012 0.8878 1.2404 0.30 0.7639 QLB:Systemic opioids 0 0 0.741 . 0.0741 QLB:TAPB 0 0 0.5694 . 0.5694 QLB:UG II-IHB 0 0.1356 . 0.1356 QLB:WI 0 0 0.3101 . 0.3101 TAPB:Systemic opioids 0 0 0.5469 . 0.5469 WI:Systemic opioids 0 0 0.2391 . 0.2391 | Control:QLB 0 0 6.2110 . 6.2110 | |
| QLB:Systemic opioids 0 0 0.0741 . 0.0741 QLB:TAPB 0 0 0.5694 . 0.5694 QLB:UG II-IHB 0 0 0.1356 . 0.1356 QLB:WI 0 0 0.3101 . 0.3101 TAPB:Systemic opioids 0 0 0.1302 . 0.1302 WG II-IHB:Systemic opioids 0 0 0.5469 | LB II-IHB:Systemic opioids 4 0.79 0.2443 0.2139 0.4058 0.5272 -0.65 0.5137 LB II-IHB:TAPB 0 0 1.8756 . 1.8756 LB II-IHB:UG II-IHB 0 0 0.4466 . 0.4466 | |
| TAPB:Systemic opioids 0 0 0.1302 . 0.1302 UG II-IHB:Systemic opioids 0 0 0.5469 . 0.5469 WI:Systemic opioids 0 0 0.2391 . 0.2391 | QLB:Systemic opioids 0 00.0741 . 0.0741 QLB:TAPB 0 00.5694 . 0.5694 QLB:UG II-IHB 0 00.1356 . 0.1356 | |
| TAPB:WI 2 0.27 0.5446 0.1712 0.8366 0.2046 -1.71 0.0867 | TAPB:Systemic opioids 0 0 0.1302 . 0.1302 UG II-IHB:Systemic opioids 0 0 0.5469 . 0.5469 WI:Systemic opioids 0 0 0.2391 . 0.2391 TAPB:UG II-IHB 0 0 0.2381 . 0.2381 | |







Postoperative nausea and vomiting during the hospital stay and at home



24